These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

73 related articles for article (PubMed ID: 7503059)

  • 21. Erythropoietin and intravenous iron therapy in postpartum anaemia.
    Wågström E; Akesson A; Van Rooijen M; Larson B; Bremme K
    Acta Obstet Gynecol Scand; 2007; 86(8):957-62. PubMed ID: 17653881
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Anemia in children with chronic kidney disease.
    Greenbaum LA
    Adv Chronic Kidney Dis; 2005 Oct; 12(4):385-96. PubMed ID: 16198278
    [TBL] [Abstract][Full Text] [Related]  

  • 23. rHuEPO in the treatment of postpartum anemia: subcutaneous versus intravenous administration.
    Zimmermann R; Breymann C; Huch R; Huch A
    Clin Investig; 1994; 72(6 Suppl):S25-30. PubMed ID: 7950168
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Recombinant human erythropoietin in anemic patients on maintenance hemodialysis: comparison between intravenous and subcutaneous administration.
    Zehnder C; Blumberg A
    Nephron; 1991; 57(4):485-6. PubMed ID: 2046836
    [No Abstract]   [Full Text] [Related]  

  • 25. Autologous blood donation with recombinant human erythropoietin in cardiac surgery: the Japanese experience.
    Baron JF
    Semin Hematol; 1996 Apr; 33(2 Suppl 2):64-7; discussion 68. PubMed ID: 8723586
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Possible influence of vitamin D receptor gene polymorphisms on recombinant human erythropoietin requirements in dialysis patients.
    Sezer S; Tutal E; Bilgic A; Ozdemir FN; Haberal M
    Transplant Proc; 2007; 39(1):40-4. PubMed ID: 17275471
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The role of anemia in the progression of congestive heart failure. Is there a place for erythropoietin and intravenous iron?
    Silverberg DS; Wexler D; Iaina A
    J Nephrol; 2004; 17(6):749-61. PubMed ID: 15593047
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Role of C-reactive protein, reticulocyte haemoglobin content and inflammatory markers in iron and erythropoietin administration in dialysis patients.
    El-Khatib M; Duncan HJ; Kant KS
    Nephrology (Carlton); 2006 Oct; 11(5):400-4. PubMed ID: 17014552
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Intravenous iron supplementation for the treatment of anaemia in pre-dialyzed chronic renal failure patients.
    Mircescu G; Gârneata L; Capusa C; Ursea N
    Nephrol Dial Transplant; 2006 Jan; 21(1):120-4. PubMed ID: 16144853
    [TBL] [Abstract][Full Text] [Related]  

  • 30. How to save money for erythropoietin therapy by changing from 'roller coaster' to continuous iron supplementation.
    Canavese C; Grill A; De Costanzi E; Martina G; Buglione E; Valente D; David O; Saitta M; Maddalena E; Barbieri S; Fop F; Salomone M; Piccoli G
    Nephron; 1999; 81(3):362-3. PubMed ID: 10050100
    [No Abstract]   [Full Text] [Related]  

  • 31. Lessons from NKF-DOQI: iron management.
    Van Wyck DB
    Semin Nephrol; 2000 Jul; 20(4):330-4. PubMed ID: 10928334
    [No Abstract]   [Full Text] [Related]  

  • 32. The use of iron in patients on chronic dialysis: mistake and misconceptions.
    Sakiewicz P; Paganini E
    J Nephrol; 1998; 11(1):5-15. PubMed ID: 9561479
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Intravenous administration of iron in epoetin-treated haemodialysis patients--which drugs, which regimen?
    Macdougall IC
    Nephrol Dial Transplant; 2000 Nov; 15(11):1743-5. PubMed ID: 11071957
    [No Abstract]   [Full Text] [Related]  

  • 34. Does intravenous erythropoietin lead to an immediate, transient increase in arterial blood pressure in dialysis patients?
    Touam M; Perez Oliva J; Zingraff J; Drüeke T
    Nephron; 1994; 67(2):240-1. PubMed ID: 8072618
    [No Abstract]   [Full Text] [Related]  

  • 35. [Optimum route for the administration of erythropoietin and iron. Effects of fractionation of small and large doses of erythropoietin].
    Arnáez-Vargas E; Faura J
    Arch Inst Biol Andina; 1970 Dec; 3(56):217-23. PubMed ID: 5526855
    [No Abstract]   [Full Text] [Related]  

  • 36. Erythropoietin and autologous blood donation.
    Hennigan T; Hocken D
    Lancet; 1989 Nov; 2(8672):1153-4. PubMed ID: 2572869
    [No Abstract]   [Full Text] [Related]  

  • 37. Intravenous administration of iron in epoetin-treated haemodialysis patients.
    Shaldon S
    Nephrol Dial Transplant; 2001 May; 16(5):1076-7. PubMed ID: 11328924
    [No Abstract]   [Full Text] [Related]  

  • 38. Recombinant human erythropoietin patient dosing algorithm.
    Muirhead N
    Semin Nephrol; 1990 Mar; 10(2 Suppl 1):59-65. PubMed ID: 2192418
    [No Abstract]   [Full Text] [Related]  

  • 39. Do oral iron supplements have any role in dialysis patients?
    Mariani LH; Berns JS
    Semin Dial; 2011; 24(4):385-7. PubMed ID: 21801222
    [No Abstract]   [Full Text] [Related]  

  • 40. Fish oil and antioxidant supplements reduce erythropoietin requirement in haemodialysis patients.
    Nordkild PK; Graff J; Jørgensen HE; Fugleberg S
    Nephrol Dial Transplant; 1993; 8(6):569. PubMed ID: 8394544
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 4.